Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIBRONEER-ACT
NCT07540988Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 20
01
Overview
A Phase 3 trial of nerandomilast in fibrosing interstitial lung disease (F-ILD), sponsored by Boehringer Ingelheim. Started Sep 2026; status: recruiting.
02
Drugs
nerandomilast
03
Conditions
fibrosing interstitial lung disease (F-ILD)
Beyond the preview
Go deeper on NCT07540988.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07540988.